TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22197613
Drug: Vatalanib 1250
Normalized name: Vatalanib
DrugBank: Vatalanib (DB04879)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vatalanib 1250 mg orally once daily
Study: 22198152
Drug: EX-527 (SIRT1
Approvals — FDA: no, EMA: no, PMDA: no
Description: EX-527 (SIRT1 inhibitor)
Study: 22198412
Drug: Lapatinib (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1,500 mg oral daily) plus Bevacizumab (10 mg/kg IV every 2 weeks)
Study: 22202188
Drug: Transcranial magnetic
Normalized name: transcranial magnetic stimulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial magnetic stimulation (TMS) followed by speech therapy (constraint-induced language therapy)
Study: 22203761
Drug: Subcutaneous GM-CSF
Normalized name: axatilimab-csfr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous GM-CSF during cycle 1 and intravenous GM-CSF during cycle 4
Study: 22203761
Drug: Subcutaneous GM-CSF
Normalized name: axatilimab-csfr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous GM-CSF at both cycles
Study: 22203761
Drug: Anti-GD2 monoclonal
Normalized name: Anti-GD2 monoclonal antibody 3F8
DrugBank: Anti-GD2 monoclonal antibody 3F8 (DB15388)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-GD2 monoclonal antibody and GM-CSF
Study: 22203761
Drug: Second-line cyclophosphamide-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line cyclophosphamide-based therapy before protocol entry
Study: 22206473
Drug: Endogenously released
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endogenously released glucose, insulin, GLP-1, ghrelin
Study: 22206473
Drug: Insulin 0-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin 0-30 min AUC
Study: 22206581
Drug: 17-hydroxyprogesterone caproate
Normalized name: 6α-Methyl-17α-hydroxyprogesterone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-hydroxyprogesterone caproate (17P) 250 mg in 1 mL castor oil, weekly intramuscular injection
Study: 22206581
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mL castor oil), weekly intramuscular injection
Study: 22210091
Drug: Panitumumab at
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab at 6 mg/kg every 14 days (cycle length = 28 days)
Study: 22212936
Drug: Sorafenib administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib administration after curative treatment (resection or ablation)
Study: 22212936
Drug: Pegylated interferon-α2a
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon-α2a long-term maintenance therapy
Study: 22215271
Drug: Office-based buprenorphine-naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office-based buprenorphine-naloxone treatment
Study: 22215271
Drug: Office-based buprenorphine-naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office-based buprenorphine-naloxone treatment with 50% price reduction
Study: 22215271
Drug: Office-based buprenorphine-naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office-based buprenorphine-naloxone treatment with alternative quality-of-life weights
Study: 22217879
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of cardioprotective drugs for 1 month or more
Study: 22218721
Drug: Weekly low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly low-dose (25,000 IU) vitamin A
Study: 22218909
Drug: Gemcitabine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine at 1,000 mg/m(2) and oxaliplatin at 100 mg/m(2) every 2 weeks
Study: 22223235
Drug: tPA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: tPA plus Argatroban (100-μg/kg bolus and infusion for 48 hours)
Study: 22223821
Drug: rFVIIIFc (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFVIIIFc (recombinant factor VIII Fc fusion protein) at doses of 25 or 65 IU/kg
Study: 22225488
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) with 1, 3, or 5 fractions for median doses of 18, 27, and 30 Gy respectively.
Study: 22225857
Drug: 30mg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg of pioglitazone after 81mg of aspirin
Study: 22228449
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg/day for 4 weeks followed by 2 weeks of rest
Study: 22228827
Drug: Telephone-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based cognitive-behavioral therapy (CBT) for depression in Parkinson disease, provided for 10 weeks, supplemented with 4 phone-based caregiver educational sessions.
Study: 22231150
Drug: Parenteral opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral opioid analgesia (morphine or hydromorphone) via patient-controlled analgesia (PCA)
Study: 22232031
Drug: Intrathecal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of cultured autologous bone marrow stromal cells (BMSCs)
Study: 22232483
Drug: β-Blocking treatment
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-Blocking treatment
Study: 22232483
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no β-Blocking treatment)
Study: 22233617
Drug: Treatment according
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment according to European guidelines on cardiovascular disease prevention
Study: 25896390
Drug: Stem Cell
Normalized name: Stem cells, apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stem Cell Educator therapy
Study: 22234716
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (most preferred CAM option)
Study: 22235096
Drug: OXi4503 (combretastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXi4503 (combretastatin A1 diphosphate, CA1P) administered intravenously at escalating doses from 0.06 to 1.92 mg/m(2), then expanded cohorts to 15.4 mg/m(2) on days 1, 8, and 15 every 28 days.
Study: 22235096
Drug: Maximum tolerated
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum tolerated dose of OXi4503 was 8.5 mg/m(2), escalation to 14 mg/m(2) was possible with temporary reversible cerebrovascular toxicity.
Study: 22235243
Drug: Weekly 135
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly 135 µg peginterferon-α 2a plus ribavirin 400 mg twice daily during 20 weeks
Study: 22236508
Drug: Invasive testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive testing (intracoronary acetylcholine administration, fast atrial pacing)
Study: 22241828
Drug: QSU-Brief questionnaire
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: QSU-Brief questionnaire administered to Black light smokers
Study: 22244711
Drug: Antithrombotic medications
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic medications continued
Study: 22244711
Drug: Antithrombotic medications
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic medications temporarily discontinued
Study: 22247403
Drug: Hippotherapy (45-minute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hippotherapy (45-minute sessions twice per week for 6 weeks)
Study: 22248486
Drug: Daily vitamin
Normalized name: Daily Vitamin Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vitamin D intake of 400 IU
Study: 22249106
Drug: Tigecycline 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigecycline 0.75 mg/kg
Study: 22249106
Drug: Tigecycline 1
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tigecycline 1 mg/kg
Study: 22249106
Drug: Tigecycline 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigecycline 1.25 mg/kg
Study: 22249106
Drug: Tigecycline 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigecycline 1.2 mg/kg q12h (predicted)
Study: 22249430
Drug: Dacomitinib 15
Normalized name: dacomitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib 15 mg QD
Study: 22249430
Drug: Dacomitinib 30
Normalized name: dacomitinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib 30 mg QD
Study: 22250979
Drug: Indinavir/ritonavir (IDV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir/ritonavir (IDV/r) 600/100 mg plus lamivudine and stavudine administered every 12 hours (bid)
Study: 22250979
Drug: Indinavir/ritonavir (IDV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir/ritonavir (IDV/r) treatment
Study: 22250979
Drug: Indinavir/ritonavir (IDV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir/ritonavir (IDV/r) treatment with concomitant rifampicin
Study: 22252944
Drug: Association of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of body fat with hormone levels
Study: 22253412
Drug: Synchronous bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Synchronous bevacizumab and erlotinib with concurrent cisplatin and twice daily radiotherapy
Study: 22258268
Drug: Increased dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased dietary sodium intake of 1000 mg/d
Study: 22258268
Drug: Top quintile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Top quintile dietary sodium consumption (>1456 mg/d)
Study: 22258268
Drug: 1000-mg/d difference
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000-mg/d difference in dietary sodium between brothers
Study: 22258271
Drug: Gluten-free diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten-free diet (GFD) with ingestion of <100 mg gluten/d
Study: 22258545
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor (letrozole 12.5 mg/day for 3 days)
Study: 22259028
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg daily dose
Study: 22260199
Drug: Spinal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal block using 10 mg 0.5% (w/v) bupivacaine
Study: 22262746
Drug: Everolimus, titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus, titrated to tolerability to achieve target trough concentrations of 5-15 ng/mL
Study: 22263047
Drug: CP +
Normalized name: methylcellulose (1500 CPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP + ASA404 (1200 mg/m(2) or 1800 mg/m(2))
Study: 22263047
Drug: CP alone
Normalized name: methylcellulose (1500 CPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP alone (Carboplatin AUC 6 mg/ml•min and Paclitaxel 175 mg/m(2))
Study: 22267606
Drug: Low-dose rituximab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rituximab (100 mg fixed dose for 4 weekly infusions) with a short course of steroids
Study: 22267607
Drug: Trastuzumab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (4 mg/kg intravenous loading dose followed by 2 mg/kg weekly)
Study: 22267687
Drug: FF/VI 400/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/VI 400/25 μg once daily for 4 weeks
Study: 22267829
Drug: 25% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% human albumin at 1.25 g/kg/day for 7 days (Tier 2)
Study: 22267829
Drug: 25% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% human albumin at 0.625 g/kg/day for 7 days (Tier 1)
Study: 22267829
Drug: 25% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% human albumin at 1.875 g/kg/day for 7 days (Tier 3)
Study: 22269862
Drug: B cell
Normalized name: B cell antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: B cell modulators such as belimumab and abatacept
Study: 22270330
Drug: GM-CSF (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (500 ug daily for 4 days starting 24 hours after each chemotherapy cycle)
Study: 22271896
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy and anti-CD20 monoclonal antibody (rituximab and Iodine I-131 tositumomab)
Study: 22272248
Drug: Intravenous ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ascorbic acid (three infusions per week)
Study: 22272248
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of gemcitabine and erlotinib
Study: 22273029
Drug: DTaP-IPV//PRP~T vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV//PRP~T vaccine booster
Study: 22274724
Drug: Primary control
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary control coping (e.g., problem solving)
Study: 22274724
Drug: Secondary control
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary control coping (e.g., acceptance)
Study: 22277685
Drug: Elevated cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated cardiac troponin T (cTnT) ≥0.01 ng/mL
Study: 22280813
Drug: DHEA (200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (200mg daily orally for 3 months)
Study: 22281831
Drug: MVA85A vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA85A vaccine (5 × 10^7 plaque-forming units)
Study: 22282683
Drug: G+GM
Normalized name: Gentamicin + Glycopeptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: G+GM
Study: 22282683
Drug: G-CSF and
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF and G+GM
Study: 22284809
Drug: Silencing TGF-β1
Normalized name: Anti-TGF-beta 2G7
DrugBank: 2G7 (DB18589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silencing TGF-β1 receptors
Study: 22284935
Drug: D-dimer threshold
Normalized name: dimer dilinoleyl dimer dilinoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-dimer threshold < 1000 ng mL(-1) with RGS ≤ 6
Study: 22284935
Drug: D-dimer threshold
Normalized name: dimer dilinoleyl dimer dilinoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-dimer threshold < 500 ng mL(-1) with RGS ≤ 6
Study: 22285963
Drug: Sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (400 mg twice daily) for 9 months
Study: 22289660
Drug: Intra-arterial administration
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial administration of autologous bone marrow-derived mononuclear cells (BMMNCs) (100-400 × 10(6) cells)
Study: 22289660
Drug: Intra-arterial administration
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial administration of autologous bone marrow-derived mononuclear cells (BMMNCs)
Study: 22289724
Drug: Oxymetazoline 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline 25 μg, 50 μg, 100 μg, and 200 μg
Study: 22289893
Drug: Costimulated tumor-derived
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Costimulated tumor-derived donor lymphocyte (TDL) infusion
Study: 22291490
Drug: ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril (5 mg/daily)
Study: 22291490
Drug: rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (4 mg/daily)
Study: 22293175
Drug: PPARγ agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPARγ agonists
Study: 22293660
Drug: Selumetinib (AZD6244)
Normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib (AZD6244) 75 mg twice daily
Study: 22294344
Drug: Anakinra 1-5
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra 1-5 mg/kg/day for at least 36 months
Study: 22298167
Drug: Intravenous dobutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dobutamine infused to achieve 80% of the maximum heart rate response for age
Study: 22298944
Drug: RebiSmart™ electronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: RebiSmart™ electronic auto-injector for subcutaneous IFN β-1a
Study: 22298950
Drug: Glycopyrrolate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (1 mg/5 mL), 0.02-0.1 mg/kg three times a day; n = 20
Study: 22300696
Drug: Antiarrhythmic medication
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic medication
Study: 22302349
Drug: Erlotinib 100
Normalized name: erlotinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 100 mg daily, gemcitabine 1,000 mg/m2, cisplatin 25 mg/m2 administered on days 1 and 8 every 3 weeks.
Study: 22302662
Drug: Procalcitonin (PCT)
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin (PCT) levels >0.21 ng/mL without antibiotic treatment
Study: 22302662
Drug: Procalcitonin (PCT)
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin (PCT) levels <0.05 ng/mL without antibiotic treatment
Study: 22302662
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of physician estimates and PCT values
Study: 22305344
Drug: Deep brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep brain stimulation (DBS) with implants; no specific dosage or duration mentioned.
Study: 22305344
Drug: Deep brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep brain stimulation (DBS) with IPG replacement; no specific dosage or duration mentioned.
Study: 22306782
Drug: valsartan 80-160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 80-160 mg
Study: 22308041
Drug: hyperinsulinemic-euglycemic plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyperinsulinemic-euglycemic plus intralipid and heparin
Study: 22308041
Drug: saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline infusion (SAL)
Study: 22308240
Drug: Daily electrocardiographic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily electrocardiographic assessments
Study: 22308288
Drug: CD20-specific CAR
Normalized name: PACIFIC OYSTER
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD20-specific CAR T-cell infusion after cyclophosphamide lymphodepletion
Study: 22308288
Drug: CD20-specific CAR
Normalized name: PACIFIC OYSTER
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD20-specific CAR T-cell infusion
Study: 22308295
Drug: plerixafor 0.24
Approvals — FDA: no, EMA: no, PMDA: no
Description: plerixafor 0.24 mg/kg/d in combination with mitoxantrone, etoposide, and cytarabine
Study: 22315486
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg for 28 days (one cycle) for a total of six cycles or until disease progression
Study: 22316567
Drug: All medication
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All medication groups
Study: 22317913
Drug: Cionni-modified capsule
Normalized name: cyclosporine, modified Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cionni-modified capsule tension ring (CTR) implantation with in-the-bag single-piece AcrySof intraocular lens (IOL) implantation
Study: 22323416
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral antidiabetes drugs (OADs)
Study: 22325452
Drug: dHER2 combined
Normalized name: dHER2 ASCI
DrugBank: SB719125 (DB16753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dHER2 combined with lapatinib (1250 mg/day)
Study: 22326470
Drug: TMC435 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC435 monotherapy (200mg once daily for 7 days)
Study: 22326470
Drug: TMC435 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC435 monotherapy (200mg once daily for 7 days) followed by PegIFN/RBV
Study: 22326922
Drug: GVAX combined
Normalized name: GVAX
DrugBank: GVAX (DB17276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GVAX combined with 3·0 mg/kg ipilimumab
Study: 22326924
Drug: Ipilimumab (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (1, 3, 5, and 10 mg/kg) in combination with PSA-Tricom vaccine (2×10^8 plaque-forming units on day 1, followed by 1×10^9 plaque-forming units monthly)
Study: 22326924
Drug: Ipilimumab and
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab and PSA-Tricom vaccine
Study: 22327873
Drug: Antecedent antihistamine
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antecedent antihistamine use
Study: 22327873
Drug: Vancomycin dose
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin dose ≥ 10 mg/kg
Study: 22327873
Drug: Vancomycin concentration
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin concentration ≥ 5 mg/mL
Study: 22329763
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pills (OCPs) - monophasic OCP (20 μg ethinyl estradiol plus 75 μg gestodene), 21/28 days per cycle, during 6 months
Study: 22329763
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pills (OCPs) with spironolactone 100 mg for 32 patients with severe hirsutism
Study: 22330017
Drug: PRO (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO (40 g of intrinsically [1-C]phenylalanine-labeled casein protein)
Study: 22333218
Drug: Bosentan 62.5
Normalized name: bosentan 62.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 62.5 mg twice daily for the first month, then up-titrated to 125 mg twice daily.
Study: 22335424
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin (1.8 mg/m2) plus rituximab (375 mg/m2)
Study: 22340331
Drug: Pressure-driven lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pressure-driven lidocaine spray (2% lidocaine) with 10 L/min oxygen flow